Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Neurol Sci ; 294(1-2): 51-6, 2010 Jul 15.
Article in English | MEDLINE | ID: mdl-20441996

ABSTRACT

We aimed to clarify the role of matrix metalloproteinases (MMP) as a possible link between neurodegeneration and skin pathology in ALS by determination of gelatinase MMP-2 and MMP-9 in spinal cord and skin of transgenic SOD1((G93A)) mice. To elucidate mechanisms influencing MMPs, markers of oxidative damage (malondialdehyde (MDA), 3-nitrotyrosine (3-NT) and 8-hydroxy-2'-deoxyguanosine (8OH2'dG)) as well as cytokines (tumor necrosis factor alpha (TNF-alpha) and interleukin 1ss (IL-1ss)) were determined. We measured MMP-9, MMP-2, 3-NT, TNF-alpha, and IL-1ss using ELISA, MDA using High Performance Liquid Chromatography (HPLC) and 8OH2'dG using HPLC with electrochemical detection (HPLC-ECD) in SOD1 and WT. MMP-9 was elevated in spinal cord and skin of SOD1 at 90 days (p=0.009, p<0.001) and 120 days (p<0.01, p=0.04). MMP-2 was elevated in the spinal cord at 90 days (p=0.01) and in the skin at 120 days (p=0.039). We observed a correlation of MMP-9 in spinal cord and skin of SOD1 (p=0.04). MDA was elevated in the spinal cord of SOD1 at 90 and 120 days (p=0.00006, p=0.01) and 8OH2'dG at 90 days (p=0.048). IL-1ss was elevated in the spinal cord of SOD1 at 120 days (p=0.02). Our data confirms that gelatinase MMPs are a common factor linking neurodegeneration and skin changes in ALS. It suggests that oxidative stress and microglial-derived cytokines contribute to the elevation of gelatinase MMPs especially in later stages of disease. Our data raises the question whether the skin may function as a biomarker for specific aspects of disease pathology in ALS.


Subject(s)
Amyotrophic Lateral Sclerosis/metabolism , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Skin/metabolism , Spinal Cord/metabolism , Aging/metabolism , Animals , Cytokines/metabolism , Disease Models, Animal , Humans , Interleukin-1beta/metabolism , Mice , Mice, Transgenic , Models, Neurological , Oxidative Stress/physiology , Superoxide Dismutase/genetics , Superoxide Dismutase/metabolism , Superoxide Dismutase-1 , Tumor Necrosis Factor-alpha/metabolism
2.
J Neurol Sci ; 285(1-2): 62-6, 2009 Oct 15.
Article in English | MEDLINE | ID: mdl-19523650

ABSTRACT

Amyotrophic lateral sclerosis (ALS) mainly affects the motor neurons but may also include other organs such as the skin. We aimed to determine whether matrix metalloproteinases could provide a link between neuronal degeneration and skin alterations in ALS. We measured CSF, serum and skin tissue MMP-2 and MMP-9 using ELISA and malondialdehyde (MDA), a marker of lipid peroxidation, using High Performance Liquid Chromatography (HPLC) in 54 ALS patients and 36 controls. We found CSF and skin MMP-9 to be elevated in ALS as compared to controls (p<0.001, p=0.03, respectively). We observed CSF MMP-9 to be highest in patients with a rapid progressive course of disease (p=0.008). In contrast, we found no significant differences of CSF, serum or skin concentrations of MMP-2 as compared to controls. CSF MMP-2 concentrations decreased with duration of disease (p=0.04, R=-0.31). MDA was elevated in serum of ALS (p<0.001), though no correlation with MMP-2 or MMP-9 was observed. Our findings indicate a general upregulation of MMP-9 in ALS. MMP-9 seems to play a role in both neurodegeneration and skin changes in ALS and could thus be a common factor linking otherwise distant aspects of disease pathology.


Subject(s)
Amyotrophic Lateral Sclerosis/cerebrospinal fluid , Amyotrophic Lateral Sclerosis/metabolism , Matrix Metalloproteinases/cerebrospinal fluid , Matrix Metalloproteinases/metabolism , Skin/metabolism , Adult , Aged , Aged, 80 and over , Amyotrophic Lateral Sclerosis/blood , Chromatography, High Pressure Liquid , Disease Progression , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Malondialdehyde/blood , Malondialdehyde/cerebrospinal fluid , Malondialdehyde/metabolism , Matrix Metalloproteinase 2/blood , Matrix Metalloproteinase 2/cerebrospinal fluid , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/blood , Matrix Metalloproteinase 9/cerebrospinal fluid , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinases/blood , Middle Aged , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL